Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-03-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific employees and executives, including exercise prices, vesting periods, and valuation methods. Since this relates to the issuance of new shares or capital-related instruments (stock options) and does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is best classified as a Regulatory Filing (RNS) as it is a mandatory disclosure of a corporate action.
2023-03-27 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from the company 'CytoGen' regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, the counterparty (Yonsei University Industry-Academic Cooperation Foundation), the contract period, and specific terms. This type of disclosure is a standard regulatory filing for material business events in the Korean market, which does not fit into specific categories like M&A, dividends, or financial reports, thus falling under the general regulatory filing category.
2023-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by the company Cytogen. It contains the auditor's opinion (unqualified/proper), key financial data (assets, liabilities, equity, profit/loss), and details regarding capital impairment and operating losses. While it provides financial data, it is a regulatory filing specifically announcing the receipt and submission of the audit report to the exchange, which is a standard requirement for public companies in Korea. It fits the 'Audit Report / Information' category as it provides the audit results and financial summary. FY 2022
2023-03-17 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 13th fiscal year (2022) of Cytogen, a KOSDAQ-listed company. It contains comprehensive financial data, business descriptions, management information, and governance details. This is the standard Korean regulatory filing equivalent to a 10-K. FY 2022
2023-03-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korean company CytoGen, specifically titled 'Change in Sales or Profit/Loss Structure of 30% or more'. This is a standard mandatory disclosure filing in the Korean market (DART system) used to report significant financial fluctuations before the final audit report is finalized. Since it provides specific financial highlights and reasons for the change rather than just announcing the publication of a report, it falls under the category of Earnings Release (ER) as it serves as the initial announcement of financial performance metrics. FY 2022
2023-03-09 Korean
파생상품거래손실발생
Capital/Financing Update Classification · 100% confidence The document is a regulatory disclosure regarding a 'Loss from Derivative Transactions' (파생상품거래손실발생) filed by the company Cytogen. It details the financial impact of derivative valuation losses related to convertible bonds. Since this is a specific regulatory disclosure of a material financial event that does not fit into standard categories like earnings releases or annual reports, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2023-03-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.